



750 BERING DRIVE
HOUSTON, TX 77057-2198
PHONE: 713.787.1400 • FAX: 713.787.1440

FACSIMILE COVER SHEET

DATE: 6/5/2003

TO: **NAME:** Examiner Dwayne Jones

COMPANY: United States Patent and Trademark Offices

FAX NO: 703-746-5065

FROM: **NAME:** Raymond Reese, Reg. No. 47,891

CONFIRMATION #: 713-787-1440 **RE: APPLICATION** Serial No. 09/995,010

NUMBER OF PAGES, INCLUDING COVER: 6 **CHARGE NUMBER:** 10379.0049.NPUS00

☐ **ORIGINAL WILL FOLLOW VIA:**

☐ **REGULAR MAIL**

☐ **OVERNIGHT DELIVERY**

☐ **HAND DELIVERY**

☐ **OTHER:** _____

☒ **ORIGINAL WILL NOT FOLLOW**

SUPPLEMENTAL MESSAGE:

Further to our telephone conversation last week, attached are proposed amendments to Application Serial No. 09/995,010. Please review the proposed amendments, in a view of the Final Office Acti n mailed May 16, 2003. Please call me at your convenience to discuss the proposed amendments. My telephone number is 713-787-1558. I am in my office Monday – Thursday mornings and all day on Fridays. Thank you for your consideration.

Sinc rely,

(Raymond) Scott Reese

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS PRIVILEGED AND CONFIDENTIAL. IT IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF THERE ARE ANY QUESTIONS OR PROBLEMS WITH THE TRANSMISSION OF THIS FACSIMILE, PLEASE CALL 713.787.1520.

H: 532103(281KN011.DOC)

Received from <17137871440> at 6/5/03 3:07:10 PM [Eastern Daylight Time]

DRAFT

Proposed Amendments in response to Final Office Action for Application Serial No. 09/995,010.

1. (Currently Amended) A method for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy, the method consisting of comprising: administering to a patient undergoing cancer chemotherapy a composition consisting of an effective amount of riboflavin; an effector of the urea cycle selected from the group consisting of arginine, ornithine or citrulline; ~~and~~ the amino acids alanine, glycine, serine, taurine, threonine and valine; and a suitable solvent, diluent, excipient or carrier.
2. (Cancelled) ~~A method according to claim 1 wherein the effector of the urea cycle is arginine, ornithine or citrulline.~~
3. The method of claim 1 wherein the amino acids are in free form or pharmacologically acceptable salts.
4. The method of claim 1, wherein the concentration of riboflavin is about 5 to about 300 mg/L.
5. The method of claim 1, wherein the concentration of the effector of the urea cycle is about 2 to about 120 mg/L.
6. The method of claim 1, wherein the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.
7. The method of claim 1, wherein said composition is administered enterally or parenterally.

8. The method of claim 1, wherein composition is administered intravenously.
9. (Cancelled) ~~The method of claim 1, wherein said composition further comprises at least one pharmaceutically acceptable carrier, diluent, or excipient.~~
10. (Currently Amended) The method of claim 1, wherein the composition consists of riboflavin, arginine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable solvent, carrier, excipient, or diluent.
11. The method of claim 10, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of arginine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.
12. (Currently Amended) The method of claim 1, wherein the composition consists of riboflavin, ornithine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable solvent, carrier, excipient, or diluent.
13. The method of claim 12, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of ornithine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.
14. (Currently Amended) A pharmaceutical composition for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy consisting of: an effective amount of riboflavin; an effector of the urea

cycle selected from the group consisting of arginine, ornithine or citrulline; and the amino acids alanine, glycine, serine, taurine, threonine, and valine; and a suitable solvent, diluent, excipient, or carrier.

15. (Currently Amended) The pharmaceutical composition of claim 14, wherein the effector of the urea cycle is ~~selected from arginine, ornithine or citrulline, wherein the effector is~~ in free form or a pharmacologically acceptable salt.

16. The pharmaceutical composition of claim 14 wherein the amino acids are in free form or pharmacologically acceptable salts.

17. The pharmaceutical composition of claim 14, wherein the concentration of riboflavin is about 5 to about 300 mg/L.

18. The pharmaceutical composition of claim 14, wherein the concentration of the effector of the urea cycle is about 2 to about 120 mg/L.

19. The pharmaceutical composition of claim 14, wherein the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

20. The pharmaceutical composition of claim 14, having a pH of about 6.0 to about 7.0.

21. (Cancelled) ~~The pharmaceutical composition of claim 14, further comprising at least one pharmaceutically acceptable carrier, diluent, or excipient.~~

22. The pharmaceutical composition of claim 14, consisting of riboflavin, arginine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable carrier or diluent.

23. The pharmaceutical composition of claim 22, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of arginine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

24. (Currently Amended) The pharmaceutical composition of claim 14, consisting of riboflavin, ornithine, alanine, glycine, serine, taurine, threonine, valine and a pharmaceutically-acceptable solvent, carrier, excipient, or diluent.

25. The pharmaceutical composition of claim 24, wherein the concentration of riboflavin is about 5 to about 300 mg/L, the concentration of ornithine is about 2 to about 120 mg/L, the concentration of alanine is about 1 to about 90 mg/L, the concentration of glycine is about 1 to about 75 mg/L, the concentration of serine is about 1 to about 75 mg/L, the concentration of taurine is about 0.5 to about 30 mg/L, the concentration of threonine is about 1 to about 90 mg/L and the concentration of valine is about 1 to about 50 mg/L.

26. (Currently Amended) A method for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy, the method consisting of comprising: administering to a patient undergoing cancer chemotherapy a composition consisting of an effective amount of riboflavin; an effector of the urea cycle comprising consisting of arginine and ornithine; ~~and~~ the amino acids alanine, glycine, serine, threonine and valine; ~~and~~ a suitable solvent, diluent, excipient, or carrier; and ~~optionally~~ 3-phenylacetyl-amino-2,6-piperidinedione.

27. (Cancelled) ~~The method of claim 26, wherein the composition further comprises of 3-phenylacetyl-amino-2,6-piperidinedione.~~

28. The method of claim 26, wherein the composition consists of 0.01-10 wt % riboflavin, 1-15 wt % arginine, and 1-15 wt % ornithine, 1-15 wt % alanine, 1-15 wt % glycine, 1-15 wt % serine, 1-15 wt % threonine 1-15 wt % valine, and 25-75 wt % 3-phenylacetyl-amino-2,6-piperidinedione.

29. (Currently Amended) A pharmaceutical composition for alleviating or reducing the toxic, nutritional and metabolic disturbances associated with cancer and cancer chemotherapy consisting of: an effective amount of riboflavin; an effector of the urea cycle consisting of comprising arginine and ornithine; ~~and~~ the amino acids alanine, glycine, serine, threonine and valine; ~~and~~ a suitable solvent, diluent, excipient, or carrier; ~~and optionally~~ 3-phenylacetyl-amino-2,6-piperidinedione.

30. (Cancelled) ~~The pharmaceutical composition of claim 29, further comprising 3-phenylacetyl-amino-2,6-piperidinedione.~~

31. The pharmaceutical composition of claim 29, consisting of 0.01-10 % riboflavin, 1-15 % arginine, and 1-15 wt % ornithine, 1-15 wt % alanine, 1-15 wt % glycine, 1-15 wt % serine, 1-15 wt % threonine 1-15 wt % valine, and 25-75 wt % 3-phenylacetyl-amino-2,6-piperidinedione.